γμβ μϊελο δςξεγ

ρψβμ πβιωεϊ

 

|
ξϊλεπιν (6,402)
|
αλμ δΰϊψ

μεεϊψιν ϊξιρδ

ων δϊψετδ αΰπβμιϊ: Levetrim Solution. ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
αρμ δαψιΰεϊ αρμ δαψιΰεϊ
|
ωϊσ α-

φεψϊ ξϊο

PER OS

ξιπεο

Solution (oral)

ωιξεω αϊψετδ

Levetrim Solution is indicated as:- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. - adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy

ξρτψ ψιωεν

150 58 33779 00

ιφψο

Trima Israel Pharmaceutical Products Maabarot Ltd, Israel

ϊεχσ ψιωιεο μϊψετδ

08/2013 - 07/2018

δϊλπιν δξετιςιν αΰϊψ ζδ πεςγε μρτχ ΰιπτεψξφιδ λμμιϊ αμαγ.
ΰιπν ξδεειν δξμφδ, ϊημισ μδϊιιςφεϊ ςν ξεξηδ ΰε χαμϊ ιιςευ ψτεΰι.
αωιξεω ΰε φτιιδ απϊεπιν ωαΰϊψ διπκ ξΰωψ ΰϊ ϊπΰι δωιξεω αΰϊψ.
ηεξψ τςιμ ψιλεζ / λξεϊ αιηιγϊ ξιπεο
Levetiracetam 100 MG/ML
ΰψιζδ λξεϊ αΰψιζδ ηιι ξγσ ϊψετϊ ξψων
Bottle glass type iii x 300 ML ηεγωιν 24 λο

*

*

χιωεψιν ιδτλε αΰετο ΰεθεξθι μμηιφιν
 

αωμιηϊ ϊβεαδ ΰπι ξχαμ ΰϊ ϊπΰι δωιξεω αΰϊψ.

 
δψων μΰϊψ εχαμ ςγλεπιν ιωιψεϊ μγεΰ"μ ωμκ!
 

πιδεμ ρτψ ξϊλεπιν

πλεο ωϊξιγ ημξϊν ςμ ρτψ ξϊλεπιν ξωμλν?
μρτψ δξϊλεπιν ωμι »
60 χμεψιεϊ
ξψχ ΰτεπδ
ξψχ ΰτεπδ ιαωδ θςιν, αψιΰ εχμ μδλπδ - ΰηγ δξψχιν δΰδεαιν αιεϊψ αηεψσ